Asset
SABIZABULIN
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04388826 | phase2 | completed | 2020-06-18 | 2020-12-18 | Veru Inc. | COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111 |
| NCT05079360 | phase2 | withdrawn | 2023-03-15 | 2024-03-30 | Veru Inc. | Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer |
| NCT04844749 | phase3 | terminated | 2021-06-24 | 2023-05-04 | Veru Inc. | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent |
| NCT05008510 | phase2 | withdrawn | 2021-12-30 | 2022-07-30 | Veru Inc. | P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC . |
| NCT03752099 | phase1_2 | terminated | 2019-01-18 | 2023-03-15 | Veru Inc. | To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer |
FDA applications (0)
This company has no applications containing this asset.